Eko Low Ejection Fraction Tool (ELEFT) vs AVIEW

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Eko Low Ejection Fraction Tool (ELEFT)

by Eko Health

AVIEW

by Coreline Soft Co.

AI Verdict

ELEFT is designed for early detection of low ejection fraction during routine physical exams using digital stethoscopes, aiding in heart failure risk identification. AVIEW, conversely, is an imaging AI platform that analyzes CT scans for the detection, diagnosis, and monitoring of lung conditions and coronary artery calcification. While both contribute to cardiac risk assessment, they utilize different data modalities and focus on distinct aspects of heart health.

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose Eko Low Ejection Fraction Tool (ELEFT) if your primary need is a rapid, non-invasive screening tool for potential low ejection fraction during routine physical examinations. This AI-powered solution is ideal for clinicians in primary care or cardiology settings who require a quick assessment of heart failure risk using a digital stethoscope, enabling early identification and timely referral for further diagnostic workup.

View Eko Low Ejection Fraction Tool (ELEFT) →

Choose AVIEW if…

Choose AVIEW if your practice requires comprehensive, AI-driven analysis of CT scans for the detailed detection, diagnosis, and monitoring of multiple thoracic conditions, including lung cancer, COPD, and coronary artery calcification. This platform is best suited for radiologists and pulmonologists needing advanced quantification, 3D visualizations, and seamless workflow integration for complex imaging studies and longitudinal patient management.

View AVIEW →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Eko Low Ejection Fraction Tool (ELEFT)	AVIEW
Pricing	Unknown	Subscription; one-off payment
Deployment	Unknown	Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Low Ejection Fraction Tool (ELEFT)

ELEFT integrates seamlessly into a routine physical exam using a digital stethoscope, providing results in approximately 15 seconds. This non-invasive, point-of-care approach makes it highly accessible and usable for a broad range of clinicians, facilitating early screening without requiring specialized imaging equipment.

Clinical Value

AVIEW

AVIEW offers a broader and deeper clinical impact by providing comprehensive solutions for the early detection, diagnosis, and monitoring of multiple life-threatening conditions, including lung cancer, COPD, and coronary artery calcification, from CT scans. Its extensive clinical validation, with over 2.5 million cases processed globally and adoption in national screening programs, demonstrates significant value in enhancing diagnostic precision and streamlining radiology workflows.

Pricing & Value

AVIEW

AVIEW offers more transparent and flexible pricing models, including subscription and one-off payment options based on installations or users. In contrast, ELEFT's pricing is listed as 'contact for pricing' as part of an enterprise platform, which provides less upfront clarity for potential buyers.

Enterprise Readiness

AVIEW

AVIEW demonstrates superior enterprise readiness with highly flexible deployment options, including cloud, hybrid, local hardware, and virtualized solutions, catering to diverse IT infrastructures. Its robust workflow automation and explicit integration with PACS/RIS/CIS, along with proven adoption in national screening programs and major U.S. medical centers, highlight its capability to fit into complex healthcare environments.

Innovation

Eko Low Ejection Fraction Tool (ELEFT)

ELEFT's innovation lies in its novel application of AI to a digital stethoscope for rapid, non-invasive detection of low ejection fraction during routine physical exams. This approach brings advanced diagnostics to the point of care, making early heart failure screening accessible in primary care and remote settings.

Support & Docs

Tie

Both Eko Health and Coreline Soft provide channels for support and documentation, including online help centers, contact information, and sales consultations. However, the available information does not provide sufficient detail to definitively distinguish the quality or comprehensiveness of their enterprise-level support and documentation offerings.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Eko Low Ejection Fraction Tool (ELEFT)	AVIEW
Name	Eko Low Ejection Fraction Tool (ELEFT)	AVIEW
Company	Eko Health	Coreline Soft Co.
Primary Application/Focus	Aids clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.	Offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
Categories	Cardiology AI, Clinical Decision Support & Reference	Cardiology AI, Oncology AI, Radiology & Imaging AI
Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Pulmonology, Radiology
Key AI Capabilities	AI-powered low ejection fraction detection, analyzes ECG and heart sound recordings, provides results in approximately 15 seconds.	AI-powered lung nodule detection and characterization, emphysema quantification, coronary artery calcium (CAC) scoring, automated segmentation, 3D visualizations, workflow automation.

Videos

Demos, reviews, and walkthroughs featuring Eko Low Ejection Fraction Tool (ELEFT) and AVIEW.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into distinct clinical workflows, and what is their primary clinical application for physicians?

Eko Low Ejection Fraction Tool (ELEFT) is designed for routine physical exams, providing rapid, non-invasive screening for low ejection fraction at the point of care using a digital stethoscope. AVIEW, conversely, integrates with PACS/RIS/CIS to enhance the diagnostic and monitoring workflow for radiologists interpreting CT scans for lung cancer, COPD, and coronary artery calcification.

What is the depth of EHR integration for each tool, and how does it facilitate the flow of patient data?

ELEFT integrates with Eko digital stethoscopes and utilizes cloud-based data processing, suggesting a pathway for data capture during exams. AVIEW explicitly offers workflow automation and integration with PACS/RIS/CIS, indicating a more direct and comprehensive integration with imaging and information systems that typically feed into EHRs.

How do these tools specifically enhance diagnostic precision and efficiency within their respective clinical contexts?

ELEFT aids in the early identification of heart failure risk during a physical exam by providing AI-powered low ejection fraction detection results in approximately 15 seconds. AVIEW enhances diagnostic precision in radiology by offering AI-powered detection and characterization of lung nodules, emphysema quantification, and coronary artery calcium scoring from CT scans, along with automated segmentations and 3D visualizations.

Considering their specialized applications, what are the key considerations for implementing each tool across multiple clinical sites?

ELEFT, being integrated with digital stethoscopes for point-of-care screening, would require equipping multiple exam rooms and training primary care or cardiology staff for its use during routine physical exams. AVIEW, focused on CT scan analysis and radiology workflows, would necessitate integration with existing PACS/RIS/CIS across imaging departments and training for radiologists and imaging technicians.

What is the anticipated learning curve for physicians, and how quickly can clinical value be realized with each tool?

ELEFT, as a non-invasive screening tool providing rapid results during a physical exam, likely has a relatively quick learning curve for basic operation and immediate value in identifying at-risk patients. AVIEW, with its comprehensive features for CT analysis, may involve a more extensive learning curve for full utilization of its advanced diagnostic and visualization capabilities, but offers significant value in streamlining complex radiology workflows and enhancing diagnostic accuracy over time.

What specific clinical problems or diagnostic gaps does each tool primarily address for a physician?

ELEFT addresses the challenge of early, non-invasive detection of low ejection fraction during routine physical exams, aiding in the proactive identification of heart failure risk, especially where traditional diagnostics like echocardiography are not readily available. AVIEW targets diagnostic precision and workflow efficiency in radiology by providing AI-powered analysis of CT scans for lung cancer, COPD, and coronary artery calcification, helping to overcome complexities in imaging interpretation and follow-up.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Eko Low Ejection Fraction Tool (ELEFT) or AVIEW

Backers

Who funded each tool's parent company.